ERR2598329
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 23
- umap1_2d
- -2.251102454
- umap2_2d
- 4.93934444
- umap1_3d
- 0.948218337
- umap2_3d
- 1.05066227
- umap3_3d
- -0.000817726
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.390
- KRAS_SIGNALING_DN+0.380
- MYOGENESIS+0.340
- COAGULATION+0.320
- INFLAMMATORY_RESPONSE+0.310
- BILE_ACID_METABOLISM+0.300
- PANCREAS_BETA_CELLS+0.300
- COMPLEMENT+0.290
- INTERFERON_ALPHA_RESPONSE+0.290
- XENOBIOTIC_METABOLISM+0.280
Top 10 suppressed
- G2M_CHECKPOINT-0.620
- E2F_TARGETS-0.610
- MYC_TARGETS_V1-0.540
- MYC_TARGETS_V2-0.420
- MITOTIC_SPINDLE-0.410
- WNT_BETA_CATENIN_SIGNALING-0.400
- DNA_REPAIR-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.350
- NOTCH_SIGNALING-0.330
- TGF_BETA_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598267 | fetal | fetal | 0.973 |
| 2 | ERR2598280 | fetal | fetal | 0.959 |
| 3 | ERR2598335 | fetal | fetal | 0.954 |
| 4 | ERR2598281 | fetal | fetal | 0.950 |
| 5 | ERR2598269 | fetal | fetal | 0.946 |
| 6 | ERR2598266 | fetal | fetal | 0.926 |
| 7 | ERR2598268 | fetal | fetal | 0.914 |
| 8 | ERR2598328 | fetal | fetal | 0.906 |
| 9 | SRR1399092 | GTEX | — | 0.897 |
| 10 | SRR1328919 | GTEX | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.380 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |